The advances of adjuvants in mRNA vaccines.
The advances of adjuvants in mRNA vaccines.
复制标题
DOI：
10.1038/s41541-023-00760-5
复制
发表时间：
2023-10-26
期刊：
影响因子：
9.2
通讯作者：
中科院分区：
文献类型：
--
作者：
针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的信使RNA（mRNA）疫苗的显著成功推动了近年来该疫苗接种技术的快速发展。在过去的三十年中，许多研究已经显示了mRNA疫苗的巨大潜力，这些疫苗在临床前研究或临床试验中引发针对病原体或癌症的保护性免疫应答。这些有效的mRNA疫苗通常含有特异性佐剂以获得所需的免疫效果。疫苗佐剂传统上是免疫增强剂，其结合先天免疫细胞的模式识别受体（PRR）以增加免疫应答的幅度或实现免疫应答的定性改变，最终增强疫苗的功效。通常，佐剂是有效疫苗的必要组成部分。根据现有文献，mRNA疫苗中的佐剂大致可分为三类：1）具有自佐剂特性的RNA，2）递送系统的组分，3）外源性免疫刺激剂。本文综述了mRNA疫苗中使用的三种佐剂，并对佐剂在mRNA疫苗中发挥作用的分子机制进行了全面的了解。
The remarkable success of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has propelled the rapid development of this vaccination technology in recent years. Over the last three decades, numerous studies have shown the considerable potential of mRNA vaccines that elicit protective immune responses against pathogens or cancers in preclinical studies or clinical trials. These effective mRNA vaccines usually contain specific adjuvants to obtain the desired immune effect. Vaccine adjuvants traditionally are immunopotentiators that bind to pattern recognition receptors (PRRs) of innate immune cells to increase the magnitude or achieve qualitative alteration of immune responses, finally enhancing the efficacy of vaccines. Generally, adjuvants are necessary parts of competent vaccines. According to the existing literature, adjuvants in mRNA vaccines can be broadly classified into three categories: 1) RNA with self-adjuvant characteristics, 2) components of the delivery system, and 3) exogenous immunostimulants. This review summarizes the three types of adjuvants used in mRNA vaccines and provides a comprehensive understanding of molecular mechanisms by which adjuvants exert their functions in mRNA vaccines.
登录
查看更多内容
影响因子：
12.4
作者：
Kariko, Katalin;Muramatsu, Hiromi;Welsh, Frank A.;Ludwig, Janos;Kato, Hiroki;Akira, Shizuo;Weissman, Drew
通讯作者：
Weissman, Drew
影响因子：
32.4
作者：
Alameh MG;Tombácz I;Bettini E;Lederer K;Sittplangkoon C;Wilmore JR;Gaudette BT;Soliman OY;Pine M;Hicks P;Manzoni TB;Knox JJ;Johnson JL;Laczkó D;Muramatsu H;Davis B;Meng W;Rosenfeld AM;Strohmeier S;Lin PJC;Mui BL;Tam YK;Karikó K;Jacquet A;Krammer F;Bates P;Cancro MP;Weissman D;Luning Prak ET;Allman D;Locci M;Pardi N
通讯作者：
Pardi N
影响因子：
7.3
作者：
Chiffoleau E
通讯作者：
Chiffoleau E
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
12.4
作者：
Bonehill, Aude;Tuyaerts, Sandra;Thielemans, Kris
通讯作者：
Thielemans, Kris